All In Biotech

Drug Trial Radar · NCT05396235

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Aug 3, 2022

Primary completion

Dec 24, 2022

Study completion Dec 24, 2022

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects

Conditions

  • Healthy Adult Males

Interventions

  • MT-3921Biological

    Solution for infusion; Intravenous (IV)

  • PlaceboBiological

    Solution for infusion; Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with adverse eventsTime frame: 16 weeks
  2. Percentage of subjects with adverse reactionsTime frame: 16 weeks
  3. Time course of serum concentrations of MT-3921Time frame: Day 1, 2, 3, 4, 8, 15, 29, 57, 85, and 113.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Hospital Tokyo

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.